FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer By Ogkologos - March 23, 2026 257 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FX-909-CLINPRO-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Cancer Research UK report highlights stark cancer inequalities across Scotland November 28, 2022 Multiple mRNA Vaccines Show Promise for Treating HPV-Related Cancers April 26, 2023 Neratinib Plus Capecitabine Outperforms Lapatinib Plus Capecitabine in Asian Patients with... November 21, 2020 Aiming to support a robust regulatory ecosystem for driving cancer research... May 12, 2026 Load more HOT NEWS Seven Extra Years How Cancer Survivors Can Overcome Common Challenges of Exercise After Treatment FDA Approves Pembrolizumab for Adjuvant Treatment of Stage IIB or IIC... Struggling Waitress Who Can’t Feed Her 4 Kids After Husband’s Cancer...
